TrialHaematologica2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Robert Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this papertrialcites it